Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC-Reference-Cited by-同舟云学术

Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC

Published:2018-04 Issue: Volume:418 Page:1-9
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Li Xue,Lian Zhen,Wang Shuai,Xing Ligang,Yu Jinming

Funder

National Health and Family Planning Commission of China

National Natural Science Foundation of China

Innovation Project of Shandong Academy of Medical Science

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference65 articles.

1. Systemic therapy for stage iv non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update;Masters;J. Clin. Oncol.,2015

2. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review;Stewart;Transl. Lung Cancer Res.,2015

3. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N. Engl. J. Med.,2017

4. Navigating the "No Man's land" of TKI-failed EGFR-mutated non-small cell lung cancer (NSCLC): a review;Oronsky;Neoplasia,2017

5. Inhibitory B7-family molecules in the tumour microenvironment;Zou;Nat. Rev. Immunol.,2008

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR Mutation and TKI Treatment Promote Secretion of Small Extracellular Vesicle PD-L1 and Contribute to Immunosuppression in NSCLC;Biomolecules;2024-07-09

2. Comparison of tissue biomarkers between non-schistosoma and schistosoma-associated urothelial carcinoma;Tissue and Cell;2024-06

3. EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment;Lung Cancer;2024-06

4. Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy;Journal of Medicinal Chemistry;2024-05-13

5. Investigation of the potential effects of estrogen receptor modulators on immune checkpoint molecules;Scientific Reports;2024-02-06